A phase 3 study of first-line sotorasib, panitumumab, and FOLFIRI versus FOLFIRI with or without bevacizumab-awwb for patients with KRAS G12C–mutated metastatic colorectal cancer (CodeBreaK 301). This ...
Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.
GlobalData on MSN3d
Amgen opens new drug substance facility in North Carolina, USSituated in the core of the NC Research Triangle, the site at Camp Helix Innovation Park is a substantial regional investment ...
Dato-DXd for breast cancer and sotorasib/panitumumab for CRC have gained FDA approval and a new drug is under FDA review for BCG-unresponsive, high-risk NMIBC. We also explore the controversy ...
At the moment there are two KRAS inhibitors on the market, Krazati and Amgen’s Lumakras (sotorasib), which are ... combination with its own EGFR drug Vectibix (panitumumab).
The multicenter, open-label, CodeBreaK 300 trial of sotorasib plus panitumumab showed consistent efficacy across key subgroups of patients with metastatic colorectal cancer harboring KRAS G12C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback